Finch Therapeutics

We were honored to recently attend the @PeggyFund's Fight #Cdiff Gala. Congrats to @DrPaulGastro for receiving the Leadership Award and Kee Kee Buckley for receiving the Advocate Award this year! We are grateful for all the incredible work that @ChristianLillis and the PLF do.

Today we announced that @DrJessicaA will be presenting CP101 PRISM-EXT data at #ACG2022 and that we have proceeded with patient dosing in PRISM4, our Ph 3 trial of CP101 in recurrent #cdiff. ir.finchtherapeutics.com/news-releases/…

If you’re attending #BIO22, we invite you to join our SVP of Research, Sonia Timberlake, for a panel discussion focused on the recent developments in the #microbiome field and the next steps for this exciting new area of drug development. For more details: bio.org/events/bio-int…

We look forward to presenting at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13th at 9:45 am ET. Tune in to learn more about our platform and pipeline of investigational #microbiome therapeutics. ir.finchtherapeutics.com/events/event-d…

Recently, our CEO Mark Smith had the pleasure of joining @patrick_oshag on the Business Breakdowns podcast. In the podcast, Mark and Patrick discuss the #microbiome and Finch’s unique approach to drug development. joincolossus.com/episodes/80480… @joincolossus

November is #cdiffawarenessmonth. We send our heartfelt gratitude to the many patients, healthcare providers, scientists, patient advocacy groups, and policy makers working together to fight #cdiff. To learn more about C. diff: cdc.gov/cdiff/index.ht… @PeggyFund @cdiffFoundation

Today at #ACG2021, we are excited for @DrJessicaA to present data from our PRISM3 Phase 2 trial of the investigational #microbiome therapeutic CP101 for the prevention of recurrent #Cdiff. We welcome ACG attendees to stop by our booth to learn more about our work (#1123).

We are excited to share data from our Phase 2 trial of CP101 for the prevention of recurrent #Cdiff at #ACG2021, including new 24-week efficacy and safety data. Stop by our booth (#1123) to learn more or click here: ir.finchtherapeutics.com/news-releases/…

We are looking forward to the Microbiome Movement Drug Development Summit. Join us on Wednesday 6/30 to hear our CEO, Mark Smith, and our Senior VP of Research, Sonia Timberlake, discuss our work harnessing the #microbiome. To register visit: microbiome-summit.com.

We are looking forward to joining the @PeggyFund's Virtual C. diff Advocacy Summit. On Thursday, April 22 at 3pm EST, our Chief Medical Officer, Zain Kassam, MD will be speaking on a panel about #cdiff and the unmet treatment needs. hopin.com/events/2021-na…

Our IPO is an exciting step that will help fuel our mission to transform lives with #microbiome therapeutics. We thank our incredible team members, board members, investors, business partners, and the clinicians and patients that have participated in our clinical trials.

On Monday November 23, the @cdiffFoundation will host a virtual Patient & Family C. diff Community Symposium. Attendees will learn more about the prevention and treatment of #cdiff and the support available to patients and their families. For more info: cdifffoundation.org/patientfamilys…

November is #cdiffawarenessmonth. We honor the patients and advocates educating and inspiring others and the healthcare professionals and scientists working to find new ways to combat #cdiff. We're honored to work alongside this community to advance patient care.

November is #cdiffawarenessmonth. To effectively fight C. diff, it’s important that infections are tracked. You can help by signing @PeggyFund’s petition to make #cdiff a Nationally Notifiable Disease. tinyurl.com/cdiffpetition

We are proud to have recently presented results from our positive PRISM3 trial of CP101 in recurrent #cdiff at #uegweek and #ACG2020. We are very grateful to the patients that participated in the trial and all the PRISM3 investigators and study staff. finchtherapeutics.com/blog/finch-the…

We look forward to the upcoming Microbiome Movement Drug Development Summit! On Mon 10/19 at 8:30am ET, our CEO Mark Smith will join the Microbiome Leaders Panel and at 12pm ET, our VP of Research Sonia Timberlake will give a presentation on our platform. microbiome-summit.com

@PeggyFund Thank you! We are so grateful for the @PeggyFund's partnership and support!

@finch_tx Congrats!

Today Finch announced a $90M Series D financing, fueling the advancement of our pipeline and bringing us one step closer to delivering on our commitment to patients affected by conditions linked to #microbiome disruption. finchtherapeutics.com/blog/finch-the…

Finch is committed to creating a more equitable, diverse and inclusive life sciences industry. As a proud signer of @MassBio’s CEO Pledge, we commit to implementing comprehensive ED&I initiatives as we do our part to eliminate racial inequality. bit.ly/3j23xeO

RT @MIT_alumni: Alum cofounded-@finch_tx is developing treatments for conditions like chronic hepatitis B, Crohn’s disease, and ulcerative colitis…all by harnessing the power of the #microbiome. bit.ly/2XMv3nK